Table 1 Characteristics of study participants in both studied groups
From: Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease
Variable | Total NAFLD group (N = 60) | Control group (N = 30) | p-value |
|---|---|---|---|
Groups | |||
Age (years) | 45.22 ± 11.4 | 31.7 ± 10.7 | < 0.001** |
Gendera | 0.013* | ||
Male/female | 16/44 | 16/14 | |
Percentage of male | 26.7% | 53.3% | |
Hypertension | 0.012* | ||
No | 49 (81.7%) | 30 (100%) | |
Yes | 11 (18.3%) | 0 (0%) | |
Diabetes | < 0.001** | ||
Absent | 29 (48.3%) | 30 (100%) | |
Oral hypoglycemic | 18 (30%) | 0 (0%) | |
On insulin | 13 (21.7%) | 0 (0%) | |
BMI (kg/m2) | 33.2 ± 7.18 | 23.99 ± 1.8 | < 0.001** |
Laboratory variables | |||
Fasting blood glucose (mg/dl) | 136.2 ± 76.8 | 93.2 ± 12.1 | 0.002** |
HB (g/dL) | 11.5 ± 1.3 | 12.7 ± 1.34 | 0.004** |
Platelets (103/μL) | 224.1 ± 73.1 | 255.04 ± 58.3 | 0.110 |
Total leucocytic count (103/μL) | 6.47 ± 1.9 | 6.81 ± 1.7 | 0.518 |
AST (U/L) | 25.7 ± 10.8 | 23.75 ± 5.8 | 0.279 |
ALT (U/L) | 29.12 ± 17.9 | 28.5 ± 6.5 | 0.815 |
Total bilirubin (mg/dL) | 0.66 ± 0.25 | 0.67 ± 0.2 | 0.947 |
ALP (U/L) | 134.17 ± 50.01 | 115.46 ± 15.6 | 0.029* |
GGT (U/L) | 66.85 ± 49.5 | 37.46 ± 23.8 | 0.002** |
Total protein (g/dL) | 7.65 ± 0.48 | 7.88 ± 0.27 | 0.014* |
Serum albumin (g/dL) | 3.75 ± 0.4 | 3.8 ± 0.28 | 0.593 |
Cholesterol (mg/dl) | 161.45±38 | 102.34 ± 24.14 | < 0.001** |
Triglycerides (mg/dl) | 161.34 ± 89.07 | 145.6 ± 29.2 | 0.230 |
HDL (mg/dl) | 51 ± 11.3 | 55.14 ± 12.3 | 0.128 |
LDL (mg/dl) | 120.4 ± 31.2 | 100.1 ± 16.2 | < 0.001** |